Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
J Immunother Cancer. 2017 Oct 17;5(1):82. doi: 10.1186/s40425-017-0287-5.
J Immunother Cancer. 2017.
PMID: 29041991
Free PMC article.